Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer |
| |
| Authors: | Xavier B. Pivot Rubi K. Li Eva S. Thomas Hyun-Cheol Chung Luis E. Fein Valorie F. Chan Jacek Jassem Fernando Hurtado de Mendoza Pralay Mukhopadyay Henri H. Roché |
| |
| Affiliation: | 1. Medical Oncology University Hospital, Service Oncologie, Boulevard Fleming, Besançon, Inserm U645, France;2. St. Luke’s Medical Center, Quezon City, The Philippines;3. Kaiser Permanente, Oakland, CA, USA;4. Yonsei Cancer Center, Seoul, Republic of Korea;5. Centro de Oncologia Rosario, Sante Fe, Argentina;6. Veterans Memorial Medical Center, Quezon City, The Philippines;7. Medical University of Gdansk, Gdansk, Poland;8. Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru;9. Bristol-Myers Squibb, Wallingford, CT, USA;10. Institut Claudius Regaud, Toulouse, France;1. Medical Research Center, Polish Academy of Sciences, Warsaw, Poland;2. Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital MSW, 02507 Warsaw, Poland;3. Central Office of the National Health Foundation, Warsaw, Poland;4. Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland;1. Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im. L. Rydygiera w Bydgoszczy, Uniwersytet Miko?aja Kopernika, Szpital Uniwersytecki nr 1 im. Jurasza w Bydgoszczy, Kierownik: prof. dr hab. n. med. Mariusz Wysocki, Poland;2. Katedra i Klinika Pediatrii, Hematologii i Onkologii, Uniwersytet Medyczny, Kierownik: prof. dr hab. n. med. El?bieta Adamkiewicz-Dro?yńska, Gdańsk, Poland;3. Klinika Onkologii Dzieci?cej, Uniwersytet Medyczny, Kierownik: prof. dr hab. n. med. Maryna Krawczuk-Rybak, Bia?ystok, Poland;4. Katedra i Klinika Pediatrii, Hematologii i Onkologii, Pomorski Uniwersytet Medyczny, Kierownik: prof. dr hab. n. med. Tomasz Urasiński, Szczecin, Poland;1. Department of Medicine, McMaster University, Hamilton, Ontario, Canada;2. Firestone Institute for Respiratory Health, St Josephs, Hamilton, Ontario, Canada;1. Medical Institute, College of Computer Science and Business Administration, Lomza, Poland;2. Department of Anatomy, Poland;3. Research Laboratory of Cosmetology, Poland;4. Department of Forensic Medicine, Poland;5. Medical College of the Universal Education Society, Lomza, Poland;6. Department of Radiology, Medical University Children Hospital, Bialystok, Poland;7. The Children''s Memorial Health Institute, Warsaw, Poland;8. Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Poland;9. Department of the Emergency Medicine and Disasters, Medical University of Bialystok, Poland;1. Department of Nephrology, Transplantology, and Internal Diseases, Medical University of Gdańsk, Gdańsk, Poland;2. Department of Clinical Immunology and Transplantology, Medical University of Gdańsk; Gdańsk, Poland;3. Kidney Transplant Regional Waiting List, Department of General Nursing, Faculty of Medical Sciences, Medical University of Gdańsk, Gdańsk, Poland;4. Department of General, Endocrine, and Transplant Surgery, Medical University of Gdańsk; Gdańsk, Poland;1. Department of Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Lodz, Lodz, Poland;2. Department of Microbiology and Laboratory Medical Immunology, Faculty of Medicine, Medical University of Lodz, Lodz, Poland |
| |
| Abstract: | ![]()
Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease.Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
